GlaxoSmithKline Stock Price, News & Analysis (NYSE:GSK)

$35.52 0.21 (0.59 %)
(As of 12/13/2017 02:16 AM ET)
Previous Close$35.31
Today's Range$35.46 - $35.59
52-Week Range$34.52 - $44.53
Volume4.65 million shs
Average Volume3.53 million shs
Market Capitalization$86.50 billion
P/E Ratio12.47
Dividend Yield5.67%
Beta0.98

About GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio2.96%
Current Ratio0.64%
Quick Ratio0.44%

Price-To-Earnings

Trailing P/E Ratio12.47
Forward P/E Ratio12.25
P/E Growth1.95

Sales & Book Value

Annual Sales$37.82 billion
Price / Sales2.31
Cash Flow$4.04 per share
Price / Cash8.80
Book Value$2.74 per share
Price / Book12.96

Profitability

Trailing EPS$1.22
Net Income$1.24 billion
Net Margins7.79%
Return on Equity115.30%
Return on Assets9.69%

Miscellaneous

Employees99,827
Outstanding Shares2,459,350,000

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Thursday, October 26th. Stockholders of record on Friday, November 10th will be given a dividend of $0.5037 per share on Thursday, January 11th. This represents a $2.01 annualized dividend and a dividend yield of 5.67%. The ex-dividend date of this dividend is Thursday, November 9th. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.49. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Wednesday, July, 29th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.03. The pharmaceutical company had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $9.14 billion. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. View GlaxoSmithKline's Earnings History.

When will GlaxoSmithKline make its next earnings announcement?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for GlaxoSmithKline.

Where is GlaxoSmithKline's stock going? Where will GlaxoSmithKline's stock price be in 2017?

16 brokerages have issued 12-month target prices for GlaxoSmithKline's stock. Their forecasts range from $37.00 to $40.00. On average, they anticipate GlaxoSmithKline's share price to reach $38.33 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a decline in short interest in November. As of November 30th, there was short interest totalling 10,397,225 shares, a decline of 22.3% from the November 15th total of 13,387,745 shares. Based on an average daily trading volume, of 4,254,511 shares, the days-to-cover ratio is currently 2.4 days. Currently, 0.4% of the company's stock are short sold.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer, Executive Director (Age 47)
  • Simon Dingemans, Chief Financial Officer, Executive Director (Age 53)
  • Patrick Vallance, President - R&D, Executive Director (Age 56)
  • Roger Connor, President - Global Manufacturing & Supply
  • Luc Debruyne, President - Global Vaccines
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare (Age 50)
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E. Troy, Senior Vice President, General Counsel

Who owns GlaxoSmithKline stock?

GlaxoSmithKline's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.52%), Hotchkis & Wiley Capital Management LLC (0.34%), Bank of New York Mellon Corp (0.24%), NWQ Investment Management Company LLC (0.11%), Equity Investment Corp (0.10%) and Macquarie Group Ltd. (0.10%). View Institutional Ownership Trends for GlaxoSmithKline.

Who sold GlaxoSmithKline stock? Who is selling GlaxoSmithKline stock?

GlaxoSmithKline's stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, OLD Republic International Corp, Saturna Capital CORP, Macquarie Group Ltd., Miller Howard Investments Inc. NY, Nationwide Fund Advisors, Kahn Brothers Group Inc. DE and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for GlaxoSmithKline.

Who bought GlaxoSmithKline stock? Who is buying GlaxoSmithKline stock?

GlaxoSmithKline's stock was acquired by a variety of institutional investors in the last quarter, including Hotchkis & Wiley Capital Management LLC, Point72 Asset Management L.P., Seatown Holdings Pte. Ltd., Fisher Asset Management LLC, NWQ Investment Management Company LLC, Sector Gamma AS, Sei Investments Co. and Crossmark Global Holdings Inc.. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy GlaxoSmithKline stock?

Shares of GlaxoSmithKline can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GlaxoSmithKline stock can currently be purchased for approximately $35.52.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $86.50 billion and generates $37.82 billion in revenue each year. The pharmaceutical company earns $1.24 billion in net income (profit) each year or $1.22 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  666 (Vote Underperform)
Total Votes:  999
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (NYSE:GSK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.262.262.402.48
Ratings Breakdown: 2 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.25$45.67$45.67$46.00
Price Target Upside: 17.29% upside26.43% upside13.88% upside5.92% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017CowenSet Price TargetHold$38.00LowView Rating Details
11/30/2017ArgusLower Price TargetBuy$40.00LowView Rating Details
11/6/2017InvestecDowngradeBuy -> HoldN/AView Rating Details
10/26/2017Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
10/24/2017J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
9/8/2017Morgan StanleyDowngradeEqual Weight -> UnderweightLowView Rating Details
7/27/2017CitigroupReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
3/7/2017BarclaysInitiated CoverageEqual WeightN/AView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche BankReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs GroupReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

GlaxoSmithKline (NYSE:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

GlaxoSmithKline (NYSE:GSK) Earnings Estimates

2017 EPS Consensus Estimate: $2.78
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.59$0.63$0.61
Q2 20171$0.71$0.71$0.71
Q3 20172$0.81$0.86$0.84
Q4 20171$0.62$0.62$0.62
(Data provided by Zacks Investment Research)

Dividends

GlaxoSmithKline (NYSE:GSK) Dividend Information

Next Dividend:1/11/2018
Annual Dividend:$1.99
Dividend Yield:5.60%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:163.12% (Trailing 12 Months of Earnings)
68.62% (Based on This Year's Estimates)
70.57% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2017quarterly$0.505.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.494.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.484.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.575.76%2/22/20172/24/20174/13/2017
10/26/2016$0.4611/2/201611/4/20161/12/2017
7/27/2016$0.498/10/20168/12/201610/13/2016
4/28/2016$0.555/11/20165/13/20167/14/2016
10/28/2015$0.5811/10/201511/13/20151/14/2016
5/7/2015quarterly$0.585.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.706.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.615.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.655.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.755.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.624.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.554.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.554.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.070.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (NYSE GSK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 9.83%
Insider Trades by Quarter for GlaxoSmithKline (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (NYSE GSK) News Headlines

Source:
DateHeadline
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the USGSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
finance.yahoo.com - December 12 at 5:27 PM
GlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from AnalystsGlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 11 at 7:42 PM
Cowen Reiterates "$38.00" Price Target for GlaxoSmithKline (GSK)Cowen Reiterates "$38.00" Price Target for GlaxoSmithKline (GSK)
www.americanbankingnews.com - December 11 at 3:40 PM
GlaxoSmithKline’s (GSK) Upgraded to HoldGlaxoSmithKline’s (GSK) Upgraded to Hold
investorplace.com - December 8 at 4:58 PM
ETFs with exposure to GlaxoSmithKline Plc : December 8, 2017ETFs with exposure to GlaxoSmithKline Plc : December 8, 2017
finance.yahoo.com - December 8 at 4:58 PM
GlaxoSmithKline’s (GSK) Upgraded to HoldGlaxoSmithKline’s (GSK) Upgraded to Hold
investorplace.com - December 8 at 12:31 PM
Interesting GSK Put And Call Options For January 2018Interesting GSK Put And Call Options For January 2018
www.nasdaq.com - December 7 at 5:27 PM
GlaxoSmithKlines Rockville chief lays out priorities for 2018GlaxoSmithKline's Rockville chief lays out priorities for 2018
finance.yahoo.com - December 7 at 5:27 PM
GlaxoSmithKline’s Consumer Healthcare Business in 3Q17GlaxoSmithKline’s Consumer Healthcare Business in 3Q17
finance.yahoo.com - December 6 at 9:58 AM
GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17
finance.yahoo.com - December 5 at 5:00 PM
GlaxoSmithKline and the Dividend MirageGlaxoSmithKline and the Dividend Mirage
finance.yahoo.com - December 5 at 5:00 PM
Glaxos Karenann Terrell Enlists AI in Understanding HIV PatientsGlaxo's Karenann Terrell Enlists AI in Understanding HIV Patients
finance.yahoo.com - December 5 at 5:00 PM
$9.89 Billion in Sales Expected for GlaxoSmithKline plc (GSK) This Quarter$9.89 Billion in Sales Expected for GlaxoSmithKline plc (GSK) This Quarter
www.americanbankingnews.com - December 5 at 9:06 AM
GlaxoSmithKline’s Business Segments in 3Q17GlaxoSmithKline’s Business Segments in 3Q17
finance.yahoo.com - December 4 at 5:03 PM
Is a Dividend Cut Coming From GlaxoSmithKline plc? - Motley FoolIs a Dividend Cut Coming From GlaxoSmithKline plc? - Motley Fool
www.fool.com - December 3 at 5:03 PM
GlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.64 Per ShareGlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.64 Per Share
www.americanbankingnews.com - December 3 at 9:26 AM
GlaxoSmithKline Begins Phase III Study On Injection To Prevent HIVGlaxoSmithKline Begins Phase III Study On Injection To Prevent HIV
www.benzinga.com - December 2 at 9:32 AM
COMM 2015-LC19 Mortgage Trust -- Moodys Affirms Six Classes of COMM 2015-LC19COMM 2015-LC19 Mortgage Trust -- Moody's Affirms Six Classes of COMM 2015-LC19
finance.yahoo.com - November 30 at 5:01 PM
GSK starts big African study of injectable drug to prevent HIVGSK starts big African study of injectable drug to prevent HIV
finance.yahoo.com - November 30 at 10:17 AM
GlaxoSmithKline (GSK) Price Target Cut to $40.00 by Analysts at ArgusGlaxoSmithKline (GSK) Price Target Cut to $40.00 by Analysts at Argus
www.americanbankingnews.com - November 30 at 8:58 AM
Better Buy: GlaxoSmithKline plc vs. PfizerBetter Buy: GlaxoSmithKline plc vs. Pfizer
www.fool.com - November 30 at 7:27 AM
GlaxoSmithKline plc (GSK) Upgraded at UBS AGGlaxoSmithKline plc (GSK) Upgraded at UBS AG
www.americanbankingnews.com - November 27 at 6:50 PM
ETFs with exposure to GlaxoSmithKline Plc : November 27, 2017ETFs with exposure to GlaxoSmithKline Plc : November 27, 2017
finance.yahoo.com - November 27 at 5:36 PM
Here"s How Walmsley Just Completed a Clean Sweep at GlaxoSmithKlineHere"s How Walmsley Just Completed a Clean Sweep at GlaxoSmithKline
finance.yahoo.com - November 24 at 4:45 PM
GlaxoSmithKline, Innoviva File For Supplementary NDA For Trelegy ElliptaGlaxoSmithKline, Innoviva File For Supplementary NDA For Trelegy Ellipta
www.rttnews.com - November 23 at 4:42 PM
A Look into the Performance of Merck’s Vaccine Portfolio in 3Q17A Look into the Performance of Merck’s Vaccine Portfolio in 3Q17
finance.yahoo.com - November 22 at 8:06 PM
Novartis (NVS) Receives EC Nod for Tasigna Label ExpansionNovartis (NVS) Receives EC Nod for Tasigna Label Expansion
finance.yahoo.com - November 22 at 8:06 PM
U.S. FDA approves first two-drug HIV regimen in win for GSKU.S. FDA approves first two-drug HIV regimen in win for GSK
finance.yahoo.com - November 22 at 5:34 AM
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instanceViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
finance.yahoo.com - November 21 at 7:16 PM
U.S. FDA approves first two-drug HIV regimen from GSKU.S. FDA approves first two-drug HIV regimen from GSK
finance.yahoo.com - November 21 at 7:16 PM
Is GlaxoSmithKline plc (LSE:GSK) Undervalued?Is GlaxoSmithKline plc (LSE:GSK) Undervalued?
finance.yahoo.com - November 20 at 7:47 PM
Slumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell - Investorplace.comSlumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell - Investorplace.com
investorplace.com - November 18 at 6:27 PM
FDA Nod For Label Expansion Of Sutent, Egalet Flies, Double Blessing For RocheFDA Nod For Label Expansion Of Sutent, Egalet Flies, Double Blessing For Roche
www.rttnews.com - November 17 at 11:50 AM
GlaxoSmithKline PLC (GSK) Given Average Recommendation of "Hold" by BrokeragesGlaxoSmithKline PLC (GSK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 16 at 5:06 PM
[$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases[$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases
finance.yahoo.com - November 16 at 2:53 PM
Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPDTrelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD
finance.yahoo.com - November 16 at 2:53 PM
Europe approves GlaxoSmithKlines new triple lung drugEurope approves GlaxoSmithKline's new triple lung drug
finance.yahoo.com - November 16 at 2:53 PM
 Brokerages Anticipate GlaxoSmithKline PLC (GSK) Will Post Quarterly Sales of $9.89 Billion Brokerages Anticipate GlaxoSmithKline PLC (GSK) Will Post Quarterly Sales of $9.89 Billion
www.americanbankingnews.com - November 16 at 2:18 AM
GlaxoSmithKline PLC (GSK) and Tetraphase Pharmaceuticals (TTPH) Financial ComparisonGlaxoSmithKline PLC (GSK) and Tetraphase Pharmaceuticals (TTPH) Financial Comparison
www.americanbankingnews.com - November 15 at 7:14 AM
$0.64 EPS Expected for GlaxoSmithKline PLC (GSK) This Quarter$0.64 EPS Expected for GlaxoSmithKline PLC (GSK) This Quarter
www.americanbankingnews.com - November 14 at 11:20 PM
Dodge & Cox Buys Eli Lilly and Co, Micro Focus International PLC, Gilead Sciences Inc, ...Dodge & Cox Buys Eli Lilly and Co, Micro Focus International PLC, Gilead Sciences Inc, ...
www.nasdaq.com - November 14 at 7:50 PM
GlaxoSmithKline PLC (GSK) Sees Large Increase in Short InterestGlaxoSmithKline PLC (GSK) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 14 at 3:58 AM
ETFs with exposure to GlaxoSmithKline Plc : November 13, 2017ETFs with exposure to GlaxoSmithKline Plc : November 13, 2017
finance.yahoo.com - November 13 at 7:21 PM
Bill Gates Is Now Tackling Alzheimer’s With a Huge Investment in Dementia ResearchBill Gates Is Now Tackling Alzheimer’s With a Huge Investment in Dementia Research
finance.yahoo.com - November 13 at 9:25 AM
GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 10th, 2017 (record date) : By the numbers : November 10, 2017GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 10th, 2017 (record date) : By the numbers : November 10, 2017
finance.yahoo.com - November 12 at 10:06 AM
Head-To-Head Review: GlaxoSmithKline PLC (GSK) vs. The CompetitionHead-To-Head Review: GlaxoSmithKline PLC (GSK) vs. The Competition
www.americanbankingnews.com - November 9 at 3:52 PM
Hikma, Vectura in dispute with FDA over generic AdvairHikma, Vectura in dispute with FDA over generic Advair
finance.yahoo.com - November 9 at 6:19 AM
Heres What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in OctoberHere's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
www.fool.com - November 8 at 12:19 PM
GlaxoSmithKline PLC (GSK) Major Shareholder Plc Glaxosmithkline Acquires 428,571 SharesGlaxoSmithKline PLC (GSK) Major Shareholder Plc Glaxosmithkline Acquires 428,571 Shares
www.americanbankingnews.com - November 8 at 12:22 AM
GlaxoSmithKline PLC (GSK) Downgraded to Hold at InvestecGlaxoSmithKline PLC (GSK) Downgraded to Hold at Investec
www.americanbankingnews.com - November 6 at 11:38 AM

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlaxoSmithKline (NYSE:GSK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlaxoSmithKline (NYSE GSK) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.